HealthTronics OssaTron
This article was originally published in The Gray Sheet
Executive Summary
Lithotripter premarket approval application submission to FDA covers treatment of plantar fasciitis (heel spurs). The filing had been delayed pending feedback from the agency on clinical trial results (1"The Gray Sheet," Sept. 6, p. 18). The 30-month, multi-site, double-blind study included over 300 patients. The Marietta, Georgia company also is pursuing additional orthopedic applications, including lateral epicondylitis (tennis elbow) and non-union fractures, for which ongoing studies will be expanded in early 2000
You may also be interested in...
HealthTronics OssaTron Lithotripter PMA Submission Planned By Year-End
A premarket approval application for HealthTronics' OssaTron lithotripter for treatment of chronic heel pain due to planar fasciitis should be submitted to FDA by December.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.